The only FDA-approved treatment for patients with Lysosomal Acid Lipase Deficiency (LAL-D)1
KANUMA® (sebelipase alfa) is a hydrolytic lysosomal cholesteryl ester and triacylglycerol–specific enzyme indicated for the treatment of patients with a diagnosis of LAL-D.1
Keep Me Updated
Be among the first to receive news and updates about KANUMA and LAL-D.
KANUMA is administered as an intravenous infusion under the supervision of a healthcare professional.1 For more information, download the full Prescribing Information and Dosing and Administration brochure below:
Getting Started on Kanuma® (sebelipase alfa)
KANUMA has been approved by the U.S. Food and Drug Administration as a treatment for patients with a diagnosis of LAL-D.1
Here’s how you can get your patients with LAL-D started on KANUMA:
Call the OneSource™ patient support program at 1-888-765-4747.
Ask your patient to sign the patient consent form to start working with his/her Nurse Case Manager.
Your office should complete the Statement of Medical Necessity (SMN) form and fax it to 1-800-420-5150 or email to Kanuma.CM@alxn.com.
We’re Here to Help
Once you have decided that KANUMA® (sebelipase alfa) is right for your patient, OneSource is here to help. Alexion’s objective is that every patient with LAL-D who can benefit from KANUMA will have access to it. After your patient signs up, they will be matched with a dedicated Alexion nurse case manager who can help answer any questions about KANUMA or LAL-D.
OneSource is staffed by nurse case managers who provide one-to-one education, assistance with funding options and access to KANUMA, as well as ongoing treatment support for your patients living with LAL-D, and their caregivers.
Our nurse case managers provide personalized support for your patients and their caregivers:
- Assistance from a dedicated nurse case manager
- Answers to questions about LAL-D or KANUMA
- Resources and education on the infusion process
- Help connecting people with other families affected by LAL-D
Financial assistance programs can help with out-of-pocket expenses for KANUMA:
- The Alexion Commercial Co-pay Program can limit out-of-pocket expense to $5 for qualifying patients with commercial insurance
- OneSource can also provide referrals to independent foundations for patients without commercial insurance and for other treatment-related costs
- OneSource nurse case managers are reimbursement experts that can also help provide information and guidance regarding the insurance approval process for benefits investigation and coverage